China Veterinary Medicine Market Research Report: Forecast (2026–2032)

China Veterinary Medicine Market Strategy, Consumer Insights, Industry Analysis, Investment Trends, Growth Opportunities, Market Size and Share, Revenue Insights, Key Segments, Ma......rket Value, Detailed Segmentation, Supply Chain Overview, Future Forecast, Market Restraints, Industry Outlook, Competitive Landscape, Market Drivers, Emerging Trends, Consumer Demand, Pricing Analysis, Strategic Insights, Leading Companies, and Market Challenges Read more

  • Healthcare
  • Jun 2026
  • 118
  • PDF, Excel, PPT

China Veterinary Medicine Market Report Key Takeaways

  • The China Veterinary Medicine Market is valued at USD 4.89 billion in 2025, rising to USD 5.11 billion in 2026, and projected to reach USD 9.29 billion by 2032.
  • The industry is projected to witness steady growth at a 10.48% CAGR during the forecast period, i.e., 2026-32.
  • Veterinary Hospitals & Clinics lead distribution channel with a 42% share in 2026.
  • In 2026, vaccines dominate product demand with 52 % share.
  • The market is moderately consolidated; the top five players collectively hold approximately 21% share.

China Veterinary Medicine Market Size and Outlook

The veterinary medicine market in China was valued at USD 4.89 billion in 2025 and is projected to grow from USD 5.11 billion in 2026 to USD 9.29 billion by 2032, registering a CAGR of 10.48% during the forecast period.

The market comprises veterinary pharmaceuticals, veterinary biologics, antiparasitic drugs, medicated feed additives, and animal nutritional supplements used across both production animal and companion animal segments. China's strong domestic animal health ecosystem provides a solid foundation for market expansion. According to a presentation by the Ministry of Agriculture and Rural Affairs (MARA) at the WOAH Regional Seminar for Veterinary Products in October 2025, China had 1,681 registered veterinary drug manufacturers in 2024, with the total output value of veterinary drug manufacturers reaching approximately USD 10.5 billion. This substantial manufacturing base highlights the country's capacity to support growing demand for veterinary healthcare products.

The regulatory environment is also contributing to market development. In December 2024, MARA's Veterinary Drug Evaluation Center introduced the "Measures for Handling Non-compliant Veterinary Drug Registration Application Documents (Trial Implementation)," which became effective on January 1, 2025. The regulation strengthens documentation requirements while streamlining approvals for compliant manufacturers, supporting higher product quality standards and improved market efficiency.

Additionally, MARA's National Action Plan for Veterinary Antimicrobial Use Reduction (2021–2025) has accelerated the adoption of alternative animal health solutions. Under the program, 223 farms across swine, poultry, and ruminant sectors were certified for meeting antimicrobial reduction standards, encouraging greater utilization of veterinary biologics, vaccines, and targeted therapeutics.

Beyond livestock production, the growing companion animal segment is creating new growth opportunities. China's pet population is estimated at approximately 124 million animals, driving rising demand for preventive healthcare products, specialty medicines, nutritional supplements, and advanced veterinary treatments. The combination of large-scale livestock production, expanding pet ownership, robust domestic manufacturing capabilities, and increasingly stringent regulatory standards is expected to sustain the long-term growth trajectory of the China veterinary medicine market through 2032.

China Veterinary Medicine Market Key Indicators

  • China's urban pet dog and cat population reached 126 million animals in 2025, including 53.43 million dogs and 72.89 million cats, up 1.8% YoY. A growing companion animal base directly increases demand for veterinary medicines, vaccines, diagnostics , and preventive healthcare products.
  • The USDA FAS GAIN report (March 2025), citing NBS data, confirmed China's live pig inventory at 427.43 million head end-2024 with a sow inventory of 40.78 million head; this world-largest active swine population creates structural demand for swine-specific vaccines, antiparasitic drugs, and pharmaceuticals.
  • A WOAH Regional Seminar country presentation (April 2024) confirmed China's cattle at 84.54 million head, goats at 132.24 million, and sheep at 194.03 million — a ruminant population exceeding, thus requiring FMD vaccines, reproductive health products, and antiparasitic treatments.
  • The American Animal Hospital Association confirmed in June 2025 that China had 30,139 registered pet hospitals as of January 2024; each hospital is a formal dispensing channel for companion animal medicines, vaccines, and diagnostics.

China Veterinary Medicine Market Scope:

 Category  Segments
By Product Biologics (Vaccines (Inactive Vaccines, Attenuated Vaccines, Recombinant Vaccines, Other Vaccines), Other Biologics), Pharmaceuticals (Parasiticides, Anti-infectives, Anti-inflammatory Drugs, Analgesics, Others)), Medicated Feed Additives
By Animal Type Production Animals (Poultry, Pigs, Cattle, Sheep & Goats, Others), Companion Animals (Dogs, Cats, Horses, Others
By Route of Administration Oral, Injectable, Topical, Other Routes of Administration
By Purpose Infectious Diseases, Parasitic Diseases, Respiratory Diseases, Gastrointestinal Diseases, Reproductive Disorders, Pain & Inflammation Management, Others
By End User Livestock Farms, Veterinary Hospitals & Clinics, Pet Care Centers, Research Institutes, Animal Owners, Others
By Distribution Channel Veterinary Hospitals & Clinics, Veterinary Pharmacies, E-commerce Platforms, Agricultural Supply Stores, Others
By Prescription Type Prescription Medicines, Over-the-Counter Medicines

China Veterinary Medicine Industry Growth Drivers

Rising Prevalence of Complex and Emerging Animal Diseases Driving Demand for Advanced Veterinary Vaccines and Pharmaceuticals

The continuous emergence of mutating animal disease strains across China is intensifying demand for advanced veterinary vaccines and disease-management pharmaceuticals. As pathogens evolve, existing vaccine formulations lose effectiveness, compelling livestock producers to procure updated biologics and targeted therapeutics, making disease complexity a direct and sustained driver of veterinary medicine expenditure.

A clear illustration is African Swine Fever. According to WOAH disease monitoring data from October 2024, ASF in China now circulates as three co-existing variants: genotype I, genotype II, and a highly lethal genotype I/II recombinant strain, with current live-attenuated vaccines offering no cross-protection against recombinant variants, forcing continuous investment in next-generation disease-control protocols across China's swine sector.

Disease management requirements intensified in 2026 when China reported its first-ever Foot-and-Mouth Disease serotype SAT1 outbreak, initially affecting 142 cattle in Xinjiang, followed by a second outbreak in Gansu. According to the UK DEFRA Preliminary Outbreak Assessment April 2026, existing FMD vaccines in China do not protect against SAT1. The continued evolution of ASF and emergence of new FMD strains is expected to sustain demand for veterinary vaccines, biologics, and animal health pharmaceuticals, supporting long-term growth of the China veterinary medicine market through 2032.

  1. Market Segmentation
  2. Introduction
    1. Product Definition
    2. Research Process
    3. Assumptions
  3. Executive Summary
  4. China Veterinary Medicine Market Policies, Regulations, and Product Standards
  5. China Veterinary Medicine Market Trends & Developments
  6. China Veterinary Medicine Market Dynamics
    1. Growth Factors
    2. Challenges
  7. China Veterinary Medicine Market Hotspot & Opportunities
  8. China Veterinary Medicine Market Outlook, 2022-2032F
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product
        1. Biologics
          1. Vaccines
            1. Inactivated
            2. Attenuated
            3. Recombinant
            4. Others
          2. Other Biologics
        2. Pharmaceuticals
          1. Anti-infectives
          2. Anti-inflammatory drugs
          3. Analgesics
          4. Parasiticides
          5. Others
        3. Medicated Feed Additives
          1. Amino acids
          2. Antibiotics & antimicrobials
          3. Others
      2. By Animal Type- Market Size & Forecast 2022-2032, USD Million
        1. Production Animals
          1. Poultry
          2. Pigs
          3. Cattle
          4. Sheep & Goats
          5. Others
        2. Companion Animals
          1. Dogs
          2. Cats
          3. Horses
          4. Others
      3. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
        1. Oral
        2. Injectable
        3. Topical
        4. Other Routes of Administration
      4. By Purpose - Market Size & Forecast 2022-2032, USD Million
        1. Infectious Diseases
        2. Parasitic Diseases
        3. Respiratory Diseases
        4. Gastrointestinal Diseases
        5. Reproductive Disorders
        6. Pain & Inflammation Management
        7. Others
      5. By End User- Market Size & Forecast 2022-2032, USD Million
        1. Livestock Farms
        2. Veterinary Hospitals & Clinics
        3. Pet Care Centers
        4. Research Institutes
        5. Animal Owners
        6. Others
      6. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
        1. Veterinary Hospitals & Clinics
        2. Veterinary Pharmacies
        3. E-commerce Platforms
        4. Agricultural Supply Stores
        5. Others
      7. By Prescription Type - Market Size & Forecast 2022-2032, USD Million
        1. Prescription Medicines
        2. Over-the-Counter Medicines
      8. By Region- Market Size & Forecast 2022-2032, USD Million
        1. North
        2. North West
        3. North East
        4. South
        5. South West
        6. East
        7. Central
      9. By Company
        1. Competition Characteristics
        2. Market Share & Analysis
  9. China Production Animals Veterinary Medicines Market Outlook, 2022-2032
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product- Market Size & Forecast 2022-2032, USD Million
      2. By Animal Type- Market Size & Forecast 2022-2032, USD Million
      3. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
      4. By Purpose - Market Size & Forecast 2022-2032, USD Million
      5. By End User- Market Size & Forecast 2022-2032, USD Million
      6. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
      7. By Prescription Type - Market Size & Forecast 2022-2032, USD Million
      8. By Region- Market Size & Forecast 2022-2032, USD Million
  10. China Companion Animals Veterinary Medicines Market Outlook, 2022-2032
    1. Market Size & Outlook
      1. By Revenues (USD Million)
    2. Market Share & Outlook
      1. By Product- Market Size & Forecast 2022-2032, USD Million
      2. By Animal Type- Market Size & Forecast 2022-2032, USD Million
      3. By Route of Administration- Market Size & Forecast 2022-2032, USD Million
      4. By Purpose - Market Size & Forecast 2022-2032, USD Million
      5. By End User- Market Size & Forecast 2022-2032, USD Million
      6. By Distribution Channel- Market Size & Forecast 2022-2032, USD Million
      7. By Prescription Type - Market Size & Forecast 2022-2032, USD Million
      8. By Region- Market Size & Forecast 2022-2032, USD Million
  11. China Veterinary Medicine Market Key Strategic Imperatives for Success & Growth
  12. Competitive Outlook
    1. Company Profiles
      1. CAHIC
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      2. Ringpu
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      3. Qilu Animal Health
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      4. Pulike
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      5. Veyong
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      6. Tairui
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      7. Weierli
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      8. Jinhe
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      9. Shengli Bio
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      10. Hisun Animal Health
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      11. Zoetis
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      12. Boehringer Ingelheim Animal Health
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      13. Merck Animal Health
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      14. Elanco Animal Health
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
      15. Ceva Santé Animale
        1. Business Description
        2. Product Portfolio
        3. Collaborations & Alliances
        4. Recent Developments
        5. Financial Details
        6. Others
  13. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Your data is 100% confidential & secure

By submitting, you agree to our Terms and Privacy Policy .

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now
Related Reports
Talk to our Consultant Talk to our Consultant
Customization Offered
  • Cross-segment Market Size & Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics & Share
  • Import Export & Production Analysis
Request Customization Request Customization